Table 1 Clinical and demographic characteristic of the patients included in the study
Characteristic | Percentage of Akkermansiaceae | X2 p-value | ||
|---|---|---|---|---|
Below median | Above median | |||
Age | ||||
< 66 years (n, %) | 21 (44.7) | 15 (71) | 6 (29) | 5.071 |
≥ 66 years (n, %) | 26 (55.3) | 10 (38) | 16 (62) | 0.02 |
Gender | ||||
Female (n, %) | 17 (36) | 10 (59) | 7 (41) | 0.339 |
Male (n, %) | 30 (64) | 15 (50) | 15 (50) | 0.56 |
Histopathology diagnosis | ||||
AC (n, %) | 28 (60) | 19 (68) | 9 (32) | 5.983 |
SCC (n, %) | 19 (40) | 6 (32) | 13 (68) | 0.014 |
Stage | ||||
IIIB (n, %) | 8 (17) | 6 (75) | 2 (25) | 1.842 |
IV (n, %) | 39 (83) | 19 (49) | 20 (51) | 0.174 |
PD-L1 (IHC) | ||||
< 50% (n, %) | 31 (66) | 15 (48) | 16 (52) | 0.844 |
≥ 50% (n, %) | 16 (34) | 10 (63) | 6 (37) | 0.358 |
Line of treatment | ||||
First line (n, %) | 12 (25) | 6 (50) | 6 (50) | 0.066 |
Second line (n, %) | 35 (75) | 19 (54) | 16 (46) | 0.797 |
Antibiotics before immunotherapy (applied up to 1–4 weeks prior to ICPs) | ||||
No (n, %) | 37 (79) | 18 (49) | 19 (51) | 1.441 |
Yes (n, %) | 10 (21) | 7 (70) | 3 (30) | 0.229 |
Smoking | ||||
No (n, %) | 7 (15) | 4 (57) | 3 (43) | 0.052 |
Yes (n, %) | 40 (85) | 21 (53) | 19 (47) | 0.819 |
Toxicity of immunotherapy | ||||
No | 33 (70) | 18 (55) | 15 (45) | 0.006 |
Yes | 14 (30) | 7 (50) | 7 (50) | 0.938 |
Response to immunotherapy | ||||
SD (n, %) | 13 (28) | 3 (23) | 10 (77) | |
PD (n, %) | 16 (34) | 12 (75) | 4 (25) | 7.751 |
PR (n, %) | 18 (38) | 9 (50) | 9 (50) | 0.02 |